What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Kymera Therapeutics Stock Skyrockets 130% Following Major Baker Bros. Investment

Kymera Therapeutics (KYMR) shares witnessed an extraordinary 130% surge following news of a significant institutional investment that bolstered market confidence. Baker Bros. Advisors, a prominent investment firm, purchased 2,005,813 shares in the biotechnology company, signaling strong conviction in its strategic direction. The transaction is valued at approximately $135.45 million, providing a substantial capital injection for the company's immunology prospects. Market analysts attribute the rally to increased optimism regarding Kymera's innovative drug development platform and pipeline. This massive investment by a specialist firm has triggered a wave of momentum trading, pushing the stock to new heights. The move underscores the substantial impact that high-conviction institutional buying can have on mid-cap healthcare equities. Investors are now closely watching how this funding will accelerate the company's clinical milestones.

Kymera Therapeutics Stock Skyrockets 130% Following Major Baker Bros. Investment

Key Facts

Instruments